Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Breast Neoplasms

Breast Diseases

Skin Diseases

Anti-Infective Agents

All Drugs and Chemicals

Formaldehyde

Lonafarnib

Tumor sample submission can consist of a fresh frozen tissue sample or a formalin-fixed paraffin embedded tissue block.

Serum is to be collected prior to the initiation of lonafarnib treatment and 28 days after the last dose of lonafarnib.

Tumor sample submission can consist of a fresh frozen tissue sample or a formalin-fixed paraffin embedded tissue block.

Tumor Sample

Serum is to be collected prior to the initiation of lonafarnib treatment and 28 days after the last dose of lonafarnib.

Serum Sample

George Sledge, M.D.

This is a tumor and serum collection study for patients with advanced breast cancer receiving treatment with lonafarnib.

OUTLINE: This is a multi-center study.

Sample Collection:

* Tumor sample
* Serum sample

Treatment Regimen:

* All registered patients must be planning treatment with lonafarnib

Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer

Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study

United States Department of Defense

Indiana University School of Medicine

Emory University

Hoosier Cancer Research Network

Respiratory Tract (Lung and Bronchial) Diseases

Lung Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Serum samples were collected from patients with lung cancer at the time of their diagnosis, prior to the initiation of treatment. Diagnosis of lung adenocarcinoma was based on pathologic analysis.

Control subjects without known cancer and aged from 40 to 75 years should meet at least one of the following criteria: (1) current or ex-smoker with at least a 10 pack-year history, (2) a first-degree relative with a history of lung cancer, or (3) a clinical diagnosis of COPD.

Serum samples were collected from patients with lung cancer at the time of their diagnosis, prior to the initiation of treatment. Diagnosis of lung squamous cell carcinoma was based on pathologic analysis.

Serum samples from lung cancer patients were collected at the time of their diagnosis, prior to the initiation of treatment. Serum samples of control subjects were collected from a biobank

serum sample

Daniel Sessler, M.D.

This study aims to evaluate the performance of serum free fatty acids as biomarkers for the identification of lung cancer.

We will compare the concentration of free fatty acids and their metabolites between patients with lung cancer and control pulmonary patients without known cancer. The diagnostic accuracy will be assessed for potential predictors.

Blood will be sampled for FFA metabolites

Serum Free Fatty Acid Metabolite Biomarkers of Lung Cancer

Biochemical analysis of serum sample was conducted by an investigator who was strictly blinded to cancer status and patient characteristics.

The Cleveland Clinic

Serum samples were collected from patients with lung cancer at the time of their diagnosis, prior to the initiation of treatment. Diagnosis of lung adenocarcinoma was based on pathologic analysis.

serum sample: Serum samples from lung cancer patients were collected at the time of their diagnosis, prior to the initiation of treatment. Serum samples of control subjects were collected from a biobank

Lung Adenocarcinoma Patients

Control subjects without known cancer and aged from 40 to 75 years should meet at least one of the following criteria: (1) current or ex-smoker with at least a 10 pack-year history, (2) a first-degree relative with a history of lung cancer, or (3) a clinical diagnosis of COPD.

serum sample: Serum samples from lung cancer patients were collected at the time of their diagnosis, prior to the initiation of treatment. Serum samples of control subjects were collected from a biobank

Control Matched to Adenocarcinoma

Serum samples were collected from patients with lung cancer at the time of their diagnosis, prior to the initiation of treatment. Diagnosis of lung squamous cell carcinoma was based on pathologic analysis.

serum sample: Serum samples from lung cancer patients were collected at the time of their diagnosis, prior to the initiation of treatment. Serum samples of control subjects were collected from a biobank

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer	NCT01232881	Breast Cancer	Tumor Sample Serum Sample	18 Years -	Hoosier Cancer Research Network
Serum Free Fatty Acid Metabolite Biomarkers of Lung Cancer	NCT01692951	Lung Cancer Biomarkers Fatty Acids	serum sample	40 Years - 80 Years	The Cleveland Clinic
Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer	NCT01232881	Breast Cancer	Tumor Sample Serum Sample	18 Years -	Hoosier Cancer Research Network

Spots Global Cancer Trial Database for serum sample

Every month we try and update this database with for serum sample cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.